Bargaining and the price of new pharmaceuticals in Australia: An empirical analysis

拟议的研究将考虑在价格和获取之间是否存在权衡，并将确定监管框架中导致无法获得替代疗法的疾病的药物供应出现延误的特点。它将为决策者提供必要的信息，以谈判可实现的最低药品价格，释放资源用于卫生部门的其他地方或减缓医疗保健支出的增长。

The proposed research will consider whether there is a trade-off between price and access and will identify features of the regulatory framework that contribute to delays in securing access to drugs for diseases with no alternative therapy. It will provide decision makers with the necessary information to negotiate the lowest achievable price for drugs, freeing up resources for use elsewhere in the health sector or slowing the growth in healthcare expenditure.